-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China’s first "Report on the Development of Rheumatoid Arthritis in China" - "Report on the Development of Rheumatoid Arthritis in China 2020", initiated by the National Center for Clinical Research on Skin and Immune Diseases (NCRC-DID), was officially published and held Rheumatoid Arthritis Development Report Interpretation Meeting", for professional interpretation of rheumatism and immunology professionals across the country
.
The "RA Annual Report" comprehensively displays the latest epidemiological data, clinical features, disease diagnosis and treatment, subject resources and construction status of China's RA, reveals the opportunities and challenges faced by China's RA diagnosis and treatment, and looks forward to the future development prospects of the subject.
Improve the standard diagnosis and treatment and long-term management of RA disease in China as a whole, and improve the diagnosis and treatment effect and quality of life of patients with rheumatism and immune diseases
.
Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and Chairman of the Rheumatology and Immunology Branch, Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, Member of the Standing Committee and Director General of the Rheumatology Branch of the Chinese Medical Doctor Association, Beijing Professor Tian Xinping, Chief Physician of the Department of Rheumatology and Immunology of Union Hospital, and Dr.
Cao Junyang, Chief Medical Officer and Vice President of Pfizer Biopharmaceutical Group China, and other guests attended the event and witnessed the official release of the "China Rheumatoid Arthritis Development Report 2020"
.
"Rheumatoid arthritis is the most common systemic rheumatism in China.
However, due to the late start of the construction of the domestic rheumatism science department, the lack of professionals, and the low awareness of patients of the disease and the lack of awareness of the importance of standardized treatment of the disease, Due to poor compliance and other comprehensive factors, RA as a whole has a certain gap with the international advanced level in standardized diagnosis and treatment and follow-up management.
" Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and President of Rheumatology and Immunology Branch, Beijing Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Xiehe Hospital, pointed out that “The Annual Report of RA” is based on patient diagnosis and treatment data from tertiary hospitals to primary medical institutions.
It provides a comprehensive survey of the characteristics and diagnosis and treatment status of domestic RA disease, and more accurately locks the overall diagnosis and treatment effect of RA.
The issue of level improvement not only provides a basis for the national health management department to formulate health policies and resource allocation, but also provides a scientific basis for the improvement of the standardized treatment level of professional groups and the development of related research, promotes the overall level of RA diagnosis and treatment in China, and improves the benefits of patients
.
"China Rheumatoid Arthritis Development Report 2020" relies on the Chinese Registry of Rheumatoid Arthritis (CREDIT), which was carried out nationwide by the National Rheumatoid Data Center (CRDC) in 2016, covering more than 300 nationwide The clinical, laboratory examination, diagnosis and treatment and prognosis data of more than 50,000 RA patients have been registered and collected by hospitals, providing first-hand data for revealing the overall picture and characteristics of RA patients in China, and reversing the long-term lack of authoritative RA disease flow in China The situation of data has laid the foundation for an in-depth understanding of the epidemiology, clinical characteristics, treatment mode, prognosis and outcome of rheumatoid arthritis in China
.
A two-pronged approach to improve the scientific understanding of RA Rheumatoid arthritis (RA) is a chronic, Highly disabling autoimmune disease, with joint swelling and pain as the most common clinical manifestation, the condition is repeated and gradually aggravated, eventually leading to joint structural damage and disability
.
In addition to joint disease, RA can also affect multiple organs and systems throughout the body
.
There are currently about 5 million RA patients in China.
However, long-term treatment, repeated episodes, joint swelling and pain, and comorbidities caused by long-term illness and medication make the patients suffer both physical and mental suffering
.
"RA Annual Report" will China's RA The characteristics of the disease are summarized as "more than four", which brings great challenges to the diagnosis and treatment of domestic RA: The number of patients is large, the average age of onset is 45 years old, and the peak onset is at 50 years old; The average time interval for a clear diagnosis is more than 2 years, and the best treatment window for RA is within 6 months to 1 year after the onset of RA.
Therefore, most patients fail to obtain early diagnosis and early treatment; there are many moderate and severe patients with severe illness
.
The report shows 34.
82% of RA patients in China have moderate disease activity, and 47.
18% of patients have severe disease activity.
There are many comorbidities.
Chinese RA patients with pulmonary interstitial lesions, fragility fractures, cardiovascular and cerebrovascular complications and tumors account for 10.
32%, 1.
97%, 3.
04% and 0.
83%
.
Professor Tian Xinping, member of the Standing Committee and Director General of the Branch of Rheumatology Specialists of the Chinese Medical Doctor Association, and chief physician of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, emphasized: "The'RA Annual Report' reminds us that RA is becoming a heavy disease burden for patients, families, and society as a whole
.
Although RA cannot be completely cured, early treatment and standardized treatment can help patients achieve disease remission, avoid or delay the occurrence of irreversible damage, and improve long-term prognosis
.
It is hoped that the official release of the "RA Annual Report" will promote the public, especially RA cognitive education for patients and families, and at the same time increase professional training for medical workers, especially grassroots medical staff, and consolidate the treatment and long-term management of'early diagnosis and early treatment','standard treatment' and'strict follow-up', Multi-party work together to improve the prognosis of patients and improve the quality of life
.
" "The scientific analysis of the current status and challenges of disease prevention and treatment by the'RA Annual Report' will point the way for the current dilemma of RA diagnosis and treatment," Professor Zeng Xiaofeng further said, "Although The rate of early RA diagnosis in China is on the rise.
However, missed and misdiagnosed RAs are still common.
In particular, grassroots medical workers have insufficient knowledge of RA, and it is difficult to implement standardized diagnosis and treatment.
It is urgently needed through academic exchanges and professional training.
, To form a unified understanding of the characteristics of China’s RA disease between medical institutions and professional RA doctors at all levels
.
In addition, due to the late start of the rheumatology and immunology disciplines in China, we should also pay attention to the expansion and development of the team of rheumatology and immunology specialists while standardizing education.
The next step is to solve the problem of the imbalance in the standardized diagnosis and treatment level of RA between different regions and different levels of hospitals in the country, and accumulate professional strength
.
" Standardized treatment, scientifically leading to change the path of the disease.
Currently, the pathogenesis of RA has not yet been fully clarified.
Clinical treatment is used to control the symptoms and symptoms of the disease.
The goal is to slow down the progression of the disease, prevent bone and joint damage, reduce the rate of disability, improve the prognosis, and improve the quality of life of patients
.
Drug therapy is still the main form of clinical treatment of RA.
Although authoritative guidelines at home and abroad clearly provide guidance for initial treatment and first-line treatment drugs, the report shows that domestic drug treatment is still not standardized, mainly manifested as "two highs and two lows.
"
.
That is, the use rate of non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids is high, the use rate of methotrexate as an anchor drug for the treatment of RA is low, and the use rate of intensive treatment drugs is low
.
It is worth noting that the use rate of the "two low" drugs is significantly lower than the average level of developed countries
.
At the same time, with the continuous deepening of basic research on RA in recent years, academic and clinical research regard RA as a disease caused by the joint action of multiple cytokines, and thus opened the chapter of precise and individualized treatment of RA, including In addition to traditional therapeutic drugs, innovative drugs such as macromolecular monoclonal antibodies and small-molecule targeted drugs JAK enzyme inhibitors also provide clinicians with more therapeutic weapons, and bring more therapeutic effects and improved quality of life for more RA patients.
New hope
.
Professor Tian Xinping said: “The report data reflects that standardized medication is the key to improving the standardization of RA diagnosis and treatment in China.
Not only must the implementation and monitoring of the recommended medications in the existing guidelines be implemented and monitored, but also the current status of RA diagnosis and treatment in China should be fully integrated in a timely manner.
Incorporate international advanced treatment experience and new drug research results into China's clinical treatment guidelines
.
In the future, with the help of professional organizations such as the National RA Research Collaboration Network, further promote the supervision and management of standardized drug use, and promote clinical research results based on real world data and scientific methods Prompt promotion in the professional field in order to bring more accurate and individualized treatment plans to more patients, change the trajectory of the disease, and improve the quality of life
.
" Dr.
Junyang Cao, Chief Medical Officer and Vice President of Pfizer Biopharmaceutical Group China, said: "Pfizer is always committed to "Bringing breakthrough innovations to patients who change their lives
.
" In recent years, through continuous exploration in the field of inflammation and immunity, we have focused on rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, alopecia areata and other diseases.
Establishing an increasingly complete pipeline of innovative drugs
.
While bringing more diversified treatment options to patients, Pfizer actively participates in strategic exploration and system construction for the prevention and management of chronic diseases including rheumatoid arthritis, and promotes large-scale reality.
World data research, on the basis of scientific understanding of diseases, scientific management of chronic diseases, and change the life trajectory for patients
.
This time I am very honored to support the release and professional interpretation of the "China Rheumatoid Arthritis Development Report 2020" as a corporate representative, and to help the industry understand the current status and challenges of RA diagnosis and treatment in China more comprehensively and accurately
.
We look forward to taking this as a starting point to gather all forces to jointly promote China's standardized diagnosis and treatment of rheumatoid arthritis in line with the international advanced level
.
"
.
The "RA Annual Report" comprehensively displays the latest epidemiological data, clinical features, disease diagnosis and treatment, subject resources and construction status of China's RA, reveals the opportunities and challenges faced by China's RA diagnosis and treatment, and looks forward to the future development prospects of the subject.
Improve the standard diagnosis and treatment and long-term management of RA disease in China as a whole, and improve the diagnosis and treatment effect and quality of life of patients with rheumatism and immune diseases
.
Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and Chairman of the Rheumatology and Immunology Branch, Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, Member of the Standing Committee and Director General of the Rheumatology Branch of the Chinese Medical Doctor Association, Beijing Professor Tian Xinping, Chief Physician of the Department of Rheumatology and Immunology of Union Hospital, and Dr.
Cao Junyang, Chief Medical Officer and Vice President of Pfizer Biopharmaceutical Group China, and other guests attended the event and witnessed the official release of the "China Rheumatoid Arthritis Development Report 2020"
.
"Rheumatoid arthritis is the most common systemic rheumatism in China.
However, due to the late start of the construction of the domestic rheumatism science department, the lack of professionals, and the low awareness of patients of the disease and the lack of awareness of the importance of standardized treatment of the disease, Due to poor compliance and other comprehensive factors, RA as a whole has a certain gap with the international advanced level in standardized diagnosis and treatment and follow-up management.
" Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and President of Rheumatology and Immunology Branch, Beijing Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Xiehe Hospital, pointed out that “The Annual Report of RA” is based on patient diagnosis and treatment data from tertiary hospitals to primary medical institutions.
It provides a comprehensive survey of the characteristics and diagnosis and treatment status of domestic RA disease, and more accurately locks the overall diagnosis and treatment effect of RA.
The issue of level improvement not only provides a basis for the national health management department to formulate health policies and resource allocation, but also provides a scientific basis for the improvement of the standardized treatment level of professional groups and the development of related research, promotes the overall level of RA diagnosis and treatment in China, and improves the benefits of patients
.
"China Rheumatoid Arthritis Development Report 2020" relies on the Chinese Registry of Rheumatoid Arthritis (CREDIT), which was carried out nationwide by the National Rheumatoid Data Center (CRDC) in 2016, covering more than 300 nationwide The clinical, laboratory examination, diagnosis and treatment and prognosis data of more than 50,000 RA patients have been registered and collected by hospitals, providing first-hand data for revealing the overall picture and characteristics of RA patients in China, and reversing the long-term lack of authoritative RA disease flow in China The situation of data has laid the foundation for an in-depth understanding of the epidemiology, clinical characteristics, treatment mode, prognosis and outcome of rheumatoid arthritis in China
.
A two-pronged approach to improve the scientific understanding of RA Rheumatoid arthritis (RA) is a chronic, Highly disabling autoimmune disease, with joint swelling and pain as the most common clinical manifestation, the condition is repeated and gradually aggravated, eventually leading to joint structural damage and disability
.
In addition to joint disease, RA can also affect multiple organs and systems throughout the body
.
There are currently about 5 million RA patients in China.
However, long-term treatment, repeated episodes, joint swelling and pain, and comorbidities caused by long-term illness and medication make the patients suffer both physical and mental suffering
.
"RA Annual Report" will China's RA The characteristics of the disease are summarized as "more than four", which brings great challenges to the diagnosis and treatment of domestic RA: The number of patients is large, the average age of onset is 45 years old, and the peak onset is at 50 years old; The average time interval for a clear diagnosis is more than 2 years, and the best treatment window for RA is within 6 months to 1 year after the onset of RA.
Therefore, most patients fail to obtain early diagnosis and early treatment; there are many moderate and severe patients with severe illness
.
The report shows 34.
82% of RA patients in China have moderate disease activity, and 47.
18% of patients have severe disease activity.
There are many comorbidities.
Chinese RA patients with pulmonary interstitial lesions, fragility fractures, cardiovascular and cerebrovascular complications and tumors account for 10.
32%, 1.
97%, 3.
04% and 0.
83%
.
Professor Tian Xinping, member of the Standing Committee and Director General of the Branch of Rheumatology Specialists of the Chinese Medical Doctor Association, and chief physician of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, emphasized: "The'RA Annual Report' reminds us that RA is becoming a heavy disease burden for patients, families, and society as a whole
.
Although RA cannot be completely cured, early treatment and standardized treatment can help patients achieve disease remission, avoid or delay the occurrence of irreversible damage, and improve long-term prognosis
.
It is hoped that the official release of the "RA Annual Report" will promote the public, especially RA cognitive education for patients and families, and at the same time increase professional training for medical workers, especially grassroots medical staff, and consolidate the treatment and long-term management of'early diagnosis and early treatment','standard treatment' and'strict follow-up', Multi-party work together to improve the prognosis of patients and improve the quality of life
.
" "The scientific analysis of the current status and challenges of disease prevention and treatment by the'RA Annual Report' will point the way for the current dilemma of RA diagnosis and treatment," Professor Zeng Xiaofeng further said, "Although The rate of early RA diagnosis in China is on the rise.
However, missed and misdiagnosed RAs are still common.
In particular, grassroots medical workers have insufficient knowledge of RA, and it is difficult to implement standardized diagnosis and treatment.
It is urgently needed through academic exchanges and professional training.
, To form a unified understanding of the characteristics of China’s RA disease between medical institutions and professional RA doctors at all levels
.
In addition, due to the late start of the rheumatology and immunology disciplines in China, we should also pay attention to the expansion and development of the team of rheumatology and immunology specialists while standardizing education.
The next step is to solve the problem of the imbalance in the standardized diagnosis and treatment level of RA between different regions and different levels of hospitals in the country, and accumulate professional strength
.
" Standardized treatment, scientifically leading to change the path of the disease.
Currently, the pathogenesis of RA has not yet been fully clarified.
Clinical treatment is used to control the symptoms and symptoms of the disease.
The goal is to slow down the progression of the disease, prevent bone and joint damage, reduce the rate of disability, improve the prognosis, and improve the quality of life of patients
.
Drug therapy is still the main form of clinical treatment of RA.
Although authoritative guidelines at home and abroad clearly provide guidance for initial treatment and first-line treatment drugs, the report shows that domestic drug treatment is still not standardized, mainly manifested as "two highs and two lows.
"
.
That is, the use rate of non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids is high, the use rate of methotrexate as an anchor drug for the treatment of RA is low, and the use rate of intensive treatment drugs is low
.
It is worth noting that the use rate of the "two low" drugs is significantly lower than the average level of developed countries
.
At the same time, with the continuous deepening of basic research on RA in recent years, academic and clinical research regard RA as a disease caused by the joint action of multiple cytokines, and thus opened the chapter of precise and individualized treatment of RA, including In addition to traditional therapeutic drugs, innovative drugs such as macromolecular monoclonal antibodies and small-molecule targeted drugs JAK enzyme inhibitors also provide clinicians with more therapeutic weapons, and bring more therapeutic effects and improved quality of life for more RA patients.
New hope
.
Professor Tian Xinping said: “The report data reflects that standardized medication is the key to improving the standardization of RA diagnosis and treatment in China.
Not only must the implementation and monitoring of the recommended medications in the existing guidelines be implemented and monitored, but also the current status of RA diagnosis and treatment in China should be fully integrated in a timely manner.
Incorporate international advanced treatment experience and new drug research results into China's clinical treatment guidelines
.
In the future, with the help of professional organizations such as the National RA Research Collaboration Network, further promote the supervision and management of standardized drug use, and promote clinical research results based on real world data and scientific methods Prompt promotion in the professional field in order to bring more accurate and individualized treatment plans to more patients, change the trajectory of the disease, and improve the quality of life
.
" Dr.
Junyang Cao, Chief Medical Officer and Vice President of Pfizer Biopharmaceutical Group China, said: "Pfizer is always committed to "Bringing breakthrough innovations to patients who change their lives
.
" In recent years, through continuous exploration in the field of inflammation and immunity, we have focused on rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, alopecia areata and other diseases.
Establishing an increasingly complete pipeline of innovative drugs
.
While bringing more diversified treatment options to patients, Pfizer actively participates in strategic exploration and system construction for the prevention and management of chronic diseases including rheumatoid arthritis, and promotes large-scale reality.
World data research, on the basis of scientific understanding of diseases, scientific management of chronic diseases, and change the life trajectory for patients
.
This time I am very honored to support the release and professional interpretation of the "China Rheumatoid Arthritis Development Report 2020" as a corporate representative, and to help the industry understand the current status and challenges of RA diagnosis and treatment in China more comprehensively and accurately
.
We look forward to taking this as a starting point to gather all forces to jointly promote China's standardized diagnosis and treatment of rheumatoid arthritis in line with the international advanced level
.
"
